Bayer (FRA:BAYN) PT Set at €90.00 by Sanford C. Bernstein

Sanford C. Bernstein set a €90.00 ($101.12) price target on Bayer (FRA:BAYN) in a report published on Wednesday, Borsen Zeitung reports. The firm currently has a buy rating on the healthcare company’s stock.

Other equities analysts also recently issued research reports about the company. Kepler Capital Markets set a €73.00 ($82.02) price objective on Bayer and gave the company a neutral rating in a research note on Thursday, June 25th. Barclays set a €80.00 ($89.89) price target on Bayer and gave the stock a buy rating in a research note on Thursday, April 9th. DZ Bank restated a buy rating on shares of Bayer in a research note on Thursday, June 25th. Berenberg Bank set a €86.00 ($96.63) target price on shares of Bayer and gave the stock a buy rating in a research report on Tuesday, June 23rd. Finally, HSBC set a €85.00 ($95.51) target price on shares of Bayer and gave the stock a buy rating in a research note on Thursday, June 25th. Five research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Bayer has a consensus rating of Buy and a consensus price target of €84.88 ($95.37).

Shares of BAYN stock opened at €66.68 ($74.92) on Wednesday. Bayer has a 52 week low of €91.58 ($102.90) and a 52 week high of €123.82 ($139.12). The firm’s 50-day simple moving average is €63.81 and its two-hundred day simple moving average is €65.30.

Bayer Company Profile

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Recommended Story: How to Use the New Google Finance Tool

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.